- The Law
Welcome to My Meds Matter
It is essential that FDA adheres to the plain language of statutes.
The current draft guidance fails to follow Congressional intent, current State laws or regulations and USP General Chapters <795> and <797> as it pertains to pharmaceutical compounding.
ASHP submitted comments strongly urging FDA to make revisions
ASHP submitted comments strongly urging FDA to make revisions to the three draft compounding guidances published in April 2016. Compounding regulation has long been a priority issue for ASHP.ASHP submitted comments strongly urging FDA to make revisions to
Calls for Members to Comment to FDA
The AVMA has submitted formal comments asking the U.S. Food and Drug Administration to work to protect veterinarians’ ability to continue using ketamine as needed to treat patients
Committee Demands Radical Policy Revisions
House Appropriations Committee says FDA policies go against Congressional intent
Addresses confusion over a compounding pharmacy’s “distribution” of compounded preparations
Senator David Vitter (R-LA) introduced S. 1406, the Saving Access to Compounded Medications for Special Needs Patients Act
Proposed policy lays out new rules for veterinarians
The U.S. Food and Drug Administration has made good on a decade-old promise to provide updated guidance on the regulatory complexities of compounding animal drugs from bulk substances.
Access to compounded medications is once again at risk because of the FDA.
Your access to compounded medications is once again at risk because of the Food and Drug Administration (FDA). Help us protect your rights and add your comments to those of physicians and patients nationwide who are telling FDA to play by the rules Congre
No front page content has been created yet.